Boehringer Ingelheim announces U.S. launch of inhalant equine asthma treatment
Boehringer Ingelheim announced the U.S. launch of the Aservo EquiHaler, which the company says is the first FDA-approved inhalant therapy for horses with severe equine asthma.
The Aservo Equihaler (ciclesonide inhalation spray), developed through collaboration between Boehringer Ingelheim’s human pharmaceutical and animal health businesses, advertises relief for the more than 10% of horses affected by severe equine asthma.
The condition is an inflammatory disease of the lower airways caused by breathing in high concentrations of organic dust particles small enough to pass with air to the lower airways. These particles are commonly found in hay and bedding.
Horses with severe equine asthma typically have clinical signs including difficulty breathing, coughing and nasal discharge, which can significantly affect the horse’s performance and quality of life. Over time, severely asthmatic horses may develop changes in the lung, making it difficult to breathe, even at rest.
The active ingredient in the Aservo Equihaler is ciclesonide, a glucocorticoid (steroid) that becomes activated in the lungs, allowing for targeted delivery.
Boehringer Ingelheim used the Respimat inhaler, developed by the company’s human pharmaceutical business, as a basis for the “Soft Mist” technology in the Aservo Equihaler. The device includes a dosing lever and nostril adaptor for smoother delivery.
“We understand the unique and inextricable link between animals and people,” said Caroline Belmont, head of U.S. global innovation and U.S. regulatory affairs at Boehringer Ingelheim Animal Health. “By delivering value through innovation, we strive to enhance the well-being of both and help shape the future direction of the industry.”